Alglucerase: Difference between revisions
No edit summary |
m (Protected "Alglucerase": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 41: | Line 41: | ||
| molecular_weight = 55597.4 g/mol | | molecular_weight = 55597.4 g/mol | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Alglucerase''' was a [[biopharmaceutical]] drug for the treatment of [[Gaucher's disease]]. It was a modified form of human β-[[glucocerebrosidase]] [[enzyme]], where the non-reducing ends of the [[oligosaccharide]] chains have been terminated with [[mannose]] [[residue (chemistry)|residue]]s.<ref name=Deegan>Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. PMID 22563238 (free full text)</ref> | '''Alglucerase''' was a [[biopharmaceutical]] drug for the treatment of [[Gaucher's disease]]. It was a modified form of human β-[[glucocerebrosidase]] [[enzyme]], where the non-reducing ends of the [[oligosaccharide]] chains have been terminated with [[mannose]] [[residue (chemistry)|residue]]s.<ref name=Deegan>Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. PMID 22563238 (free full text)</ref> | ||
| Line 48: | Line 53: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==External links== | ==External links== | ||
| Line 56: | Line 61: | ||
[[Category:Hydrolases]] | [[Category:Hydrolases]] | ||
[[Category:Drug]] | |||
Latest revision as of 17:20, 18 August 2015
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692001 |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 3.6–10.4 min |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C2532H3854N672O711S16 |
| Molar mass | 55597.4 g/mol |
  (what is this?) (verify) | |
|
WikiDoc Resources for Alglucerase |
|
Articles |
|---|
|
Most recent articles on Alglucerase Most cited articles on Alglucerase |
|
Media |
|
Powerpoint slides on Alglucerase |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alglucerase at Clinical Trials.gov Clinical Trials on Alglucerase at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alglucerase
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alglucerase Discussion groups on Alglucerase Patient Handouts on Alglucerase Directions to Hospitals Treating Alglucerase Risk calculators and risk factors for Alglucerase
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alglucerase |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.[1]
Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug appoved as an enzyme replacement therapy.[1]
It was approved by the FDA in 1991.[2] It has been withdrawn from the market[3][4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture[1] (see imiglucerase).
References
- ↑ 1.0 1.1 1.2 1.3 Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. PMID 22563238 (free full text)
- ↑ World Health Organization. Regulatory Matters WHO Drug Information 5:3) 1991. p 123
- ↑ Aetna. Last reviewed 8 August, 2014 Clinical Policy Bulletin Number: 0442: Enzyme-replacement Therapy for Lysosomal Storage Disorders
- ↑ FDA Prescription and Over-the-Counter Drug Product List. 32ND Edition Cumulative Supplement Number 3: March 2012. Additions/Deletions for Prescription Drug Product List
External links
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Infobox drug tracked parameters
- Hydrolases
- Drug